Digital 9 Infrastructure (DGI9) has published its audited results for the year ended 31 December 2024, a pivotal period for the company as it transitioned to a managed wind-down under the oversight of new investment manager InfraRed Capital Partners. The year saw key asset sales completed or agreed, but also a substantial markdown in NAV […]
We also have: Stories you may have missed from yesterday:
HydrogenOne Capital Growth (HGEN) has published its annual results for the year ended 31 December 2024, reporting solid operational progress across its portfolio but a marked fall in NAV and a hefty drop in share price amid sector-specific and macroeconomic challenges. NAV fell by 12.2% over the year to £116.4m, or 90.39p per share, down […]
BBGI Global Infrastructure (BBGI) has provided an update on the recommended cash offer from Boswell Holdings 3 S.C.Sp. (Bidco), a newly formed vehicle indirectly controlled by British Columbia Investment Management Corporation (BCI). As of 29 April 2025, Bidco has received valid acceptances covering just 2.73% of BBGI’s issued share capital. The offer, which was first […]
GCP Asset Backed Income (GABI) has published its results for the year ended 31 December 2024, marking a year of significant progress in its managed wind-down strategy. Following shareholder approval in May 2024, the company amended its investment policy to focus on an orderly realisation of assets and the return of capital to investors. During […]
CEIBA Investments has published its annual results for the year ended 31 December 2024, highlighting a tough year for the company, driven largely by deteriorating conditions in Cuba and geopolitical developments. The company saw its net asset value (NAV) fall 18.0% in US dollar terms to US$130.0m, with the NAV per share down to US$0.94 […]
Jade Biosciences, a portfolio company of RTW Biotech Opportunities (RTW), has merged with Nasdaq-listed Aerovate Therapeutics. The combined business will continue under the name Jade Biosciences, Inc. and trade on Nasdaq under the ticker JBIO. Jade is a privately held biotech firm focused on developing therapies for autoimmune diseases. Its lead candidate, JADE-001, is expected […]
NB Distressed Debt Investment Fund has published its 2024 annual report, providing an update on realisations, distributions, and plans for the fund’s eventual wind-down. The company reported mixed performance across its share classes during the year, though it says it has entered what it hopes will be the final stage of asset harvesting. Since inception, […]
HydrogenOne Capital Growth (HGEN) has released its 2024 sustainability report, highlighting progress in greenhouse gas (GHG) emissions reduction and the fund’s ongoing focus on climate-aligned investing. The company, which is the first London-listed fund dedicated to clean hydrogen, continues to position itself as a key player in the energy transition. The report shows that during […]
[QD comment MR: It is good to see one of PPET’s directors making a significant addition to his personal investment in the trust as it both significantly improves alignment with other shareholders and is also a sign of confidence in PPET’s private equity strategy in these times of increased market turbulence.] We also have: Stories […]
